Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2022 | Nov. 08, 2022 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000811212 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2022 | |
Document Transition Report | false | |
Entity File Number | 333-82900 | |
Entity Registrant Name | ThermoGenesis Holdings, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 94-3018487 | |
Entity Address, Address Line One | 2711 Citrus Road | |
Entity Address, City or Town | Rancho Cordova | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95742 | |
City Area Code | 916 | |
Local Phone Number | 858-5100 | |
Title of 12(b) Security | Common Stock, $.001 par value | |
Trading Symbol | THMO | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 45,997,792 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 3,903,000 | $ 7,280,000 |
Accounts receivable, net of allowance for doubtful accounts of $149,000 ($156,000 at December 31, 2021) | 2,056,000 | 733,000 |
Inventories | 4,912,000 | 5,373,000 |
Prepaid expenses and other current assets | 612,000 | 1,578,000 |
Total current assets | 11,483,000 | 14,964,000 |
Inventories non-current, net | 930,000 | 1,709,000 |
Equipment and leasehold improvements, net | 1,271,000 | 1,261,000 |
Right-of-use operating lease assets, net | 426,000 | 571,000 |
Goodwill | 781,000 | 781,000 |
Other intangible assets, net | 1,294,000 | 1,318,000 |
Other assets | 255,000 | 48,000 |
Total assets | 20,093,000 | 20,652,000 |
Current liabilities: | ||
Accounts payable | 1,007,000 | 1,280,000 |
Accrued payroll and related expenses | 493,000 | 348,000 |
Deferred revenue – short-term | 841,000 | 719,000 |
Convertible promissory note – related party | 5,133,000 | |
Interest payable – related party | 1,099,000 | 2,231,000 |
Convertible promissory note, net | 1,000,000 | 813,000 |
Other current liabilities | 1,395,000 | 957,000 |
Total current liabilities | 10,968,000 | 6,348,000 |
Convertible promissory note – related party, net | 9,245,000 | |
Operating lease obligations – long-term | 205,000 | 398,000 |
Deferred revenue – long-term | 1,014,000 | 1,244,000 |
Other noncurrent liabilities | 18,000 | 20,000 |
Total liabilities | 15,827,000 | 17,255,000 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value; 350,000,000 shares authorized; 31,321,362 issued and outstanding (11,911,784 at December 31, 2021) | 31,000 | 12,000 |
Additional paid in capital | 267,731,000 | 268,447,000 |
Accumulated deficit | (262,761,000) | (264,662,000) |
Accumulated other comprehensive loss | 98,000 | 31,000 |
Total ThermoGenesis Holdings, Inc. stockholders’ equity | 5,099,000 | 3,828,000 |
Noncontrolling interests | (833,000) | (431,000) |
Total equity | 4,266,000 | 3,397,000 |
Total liabilities and equity | 20,093,000 | $ 20,652,000 |
Lease Agreement with Z3 Investment LLC [Member] | ||
Current assets: | ||
Right-of-use operating lease assets, net | 3,653,000 | |
Current liabilities: | ||
Operating lease obligations – long-term | $ 3,622,000 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited)-parentheticals (Parentheticals) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Accounts receivable, allowance for doubtful accounts | $ 149,000 | $ 156,000 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 2,000,000 | 2,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 350,000,000 | 350,000,000 |
Common Stock, Shares, Issued (in shares) | 31,321,362 | 11,911,784 |
Common stock, shares outstanding (in shares) | 31,321,362 | 11,911,784 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Net revenues | $ 2,115,000 | $ 3,158,000 | $ 7,807,000 | $ 6,876,000 |
Cost of revenues | 1,678,000 | 2,043,000 | 5,491,000 | 4,067,000 |
Gross profit | 437,000 | 1,115,000 | 2,316,000 | 2,809,000 |
Expenses: | ||||
Selling, general and administrative | 1,982,000 | 1,677,000 | 5,665,000 | 7,171,000 |
Research and development | 470,000 | 543,000 | 1,317,000 | 1,544,000 |
Total operating expenses | 2,452,000 | 2,220,000 | 6,982,000 | 8,715,000 |
Loss from operations | (2,015,000) | (1,105,000) | (4,666,000) | (5,906,000) |
Other expenses: | ||||
Interest expense | (1,391,000) | (1,530,000) | (3,572,000) | (4,573,000) |
Gain on extinguishment of debt | 652,000 | |||
Other income/(expense) | 3,000 | 843,000 | (1,000) | 833,000 |
Total other expense | (1,388,000) | (687,000) | (3,573,000) | (3,088,000) |
Net loss | (3,403,000) | (1,792,000) | (8,239,000) | (8,994,000) |
Loss attributable to noncontrolling interests | (163,000) | (18,000) | (402,000) | (269,000) |
Net loss attributable to common stockholders | (3,240,000) | (1,774,000) | (7,837,000) | (8,725,000) |
Net loss | (3,403,000) | (1,792,000) | (8,239,000) | (8,994,000) |
Other comprehensive loss: | ||||
Foreign currency translation adjustments gain (loss) | 22,000 | (1,000) | 67,000 | 12,000 |
Comprehensive loss | (3,381,000) | (1,793,000) | (8,172,000) | (8,982,000) |
Comprehensive loss attributable to noncontrolling interests | (163,000) | (18,000) | (402,000) | (269,000) |
Comprehensive loss attributable to common stockholders | $ (3,218,000) | $ (1,775,000) | $ (7,770,000) | $ (8,713,000) |
Per share data: | ||||
Basic and diluted net loss per common share (in dollars per share) | $ (0.10) | $ (0.15) | $ (0.41) | $ (0.74) |
Weighted average common shares outstanding – basic and diluted (in shares) | 31,265,797 | 11,911,784 | 19,075,331 | 11,757,211 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($) | Common Stock [Member] At The Market Offering Agreement [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] Cumulative Effect, Period of Adoption, Adjustment [Member] | Additional Paid-in Capital [Member] At The Market Offering Agreement [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjustment [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | At The Market Offering Agreement [Member] | Total |
Balance (in shares) at Dec. 31, 2020 | 8,934,952 | |||||||||||
Balance at Dec. 31, 2020 | $ 9,000 | $ 259,058,000 | $ (253,283,000) | $ 16,000 | $ 70,000 | $ 5,870,000 | ||||||
Stock-based compensation expense | 258,000 | 258,000 | ||||||||||
Issuance of common stock via at-the-market offering, net (in shares) | 2,976,832 | |||||||||||
Issuance of common stock via at-the-market offering, net | $ 3,000 | $ 6,829,000 | $ 6,832,000 | |||||||||
Foreign currency translation gain | 1,000 | 1,000 | ||||||||||
Net loss | (2,413,000) | (118,000) | (2,531,000) | |||||||||
Balance (in shares) at Mar. 31, 2021 | 11,911,784 | |||||||||||
Balance at Mar. 31, 2021 | $ 12,000 | 266,145,000 | (255,696,000) | 17,000 | (48,000) | 10,430,000 | ||||||
Balance (in shares) at Dec. 31, 2020 | 8,934,952 | |||||||||||
Balance at Dec. 31, 2020 | $ 9,000 | 259,058,000 | (253,283,000) | 16,000 | 70,000 | 5,870,000 | ||||||
Foreign currency translation gain | 12,000 | |||||||||||
Balance (in shares) at Sep. 30, 2021 | 11,911,784 | |||||||||||
Balance at Sep. 30, 2021 | $ 12,000 | 268,336,000 | (262,009,000) | 28,000 | (199,000) | 6,168,000 | ||||||
Balance (in shares) at Mar. 31, 2021 | 11,911,784 | |||||||||||
Balance at Mar. 31, 2021 | $ 12,000 | 266,145,000 | (255,696,000) | 17,000 | (48,000) | 10,430,000 | ||||||
Stock-based compensation expense | 2,099,000 | 2,099,000 | ||||||||||
Foreign currency translation gain | 12,000 | 12,000 | ||||||||||
Net loss | (4,539,000) | (133,000) | (4,672,000) | |||||||||
Balance (in shares) at Jun. 30, 2021 | 11,911,784 | |||||||||||
Balance at Jun. 30, 2021 | $ 12,000 | 268,244,000 | (260,235,000) | 29,000 | (181,000) | 7,869,000 | ||||||
Stock-based compensation expense | 92,000 | 92,000 | ||||||||||
Foreign currency translation gain | (1,000) | (1,000) | ||||||||||
Net loss | (1,774,000) | (18,000) | (1,792,000) | |||||||||
Balance (in shares) at Sep. 30, 2021 | 11,911,784 | |||||||||||
Balance at Sep. 30, 2021 | $ 12,000 | 268,336,000 | (262,009,000) | 28,000 | (199,000) | 6,168,000 | ||||||
Balance (in shares) at Dec. 31, 2021 | 11,911,784 | |||||||||||
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021 | $ (10,681,000) | $ 9,739,000 | $ (942,000) | |||||||||
Balance at Dec. 31, 2021 | $ 12,000 | 268,447,000 | (264,662,000) | 31,000 | (431,000) | 3,397,000 | ||||||
Stock-based compensation expense | 42,000 | 42,000 | ||||||||||
Issuance of common stock via at-the-market offering, net (in shares) | 918,093 | |||||||||||
Issuance of common stock via at-the-market offering, net | $ 1,000 | 593,000 | $ 594,000 | |||||||||
Related party convertible note price reset | 213,000 | 213,000 | ||||||||||
Foreign currency translation gain | 14,000 | 14,000 | ||||||||||
Net loss | (1,910,000) | (126,000) | (2,036,000) | |||||||||
Balance (in shares) at Mar. 31, 2022 | 12,829,877 | |||||||||||
Balance at Mar. 31, 2022 | $ 13,000 | 258,614,000 | (256,833,000) | 45,000 | (557,000) | 1,282,000 | ||||||
Balance (in shares) at Dec. 31, 2021 | 11,911,784 | |||||||||||
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021 | $ (10,681,000) | $ 9,739,000 | $ (942,000) | |||||||||
Balance at Dec. 31, 2021 | $ 12,000 | 268,447,000 | (264,662,000) | 31,000 | (431,000) | 3,397,000 | ||||||
Issuance of common stock via at-the-market offering, net (in shares) | 8,857,344 | |||||||||||
Related party convertible note price reset | 3,763,000 | |||||||||||
Foreign currency translation gain | 67,000 | |||||||||||
Balance (in shares) at Sep. 30, 2022 | 31,321,362 | |||||||||||
Balance at Sep. 30, 2022 | $ 31,000 | 267,731,000 | (262,761,000) | 98,000 | (833,000) | 4,266,000 | ||||||
Balance (in shares) at Mar. 31, 2022 | 12,829,877 | |||||||||||
Balance at Mar. 31, 2022 | $ 13,000 | 258,614,000 | (256,833,000) | 45,000 | (557,000) | 1,282,000 | ||||||
Stock-based compensation expense | 72,000 | 72,000 | ||||||||||
Issuance of common stock via at-the-market offering, net (in shares) | 4,397,329 | 1,450,000 | ||||||||||
Issuance of common stock via at-the-market offering, net | $ 4,000 | 1,446,000 | ||||||||||
Related party convertible note price reset | 2,475,000 | 2,475,000 | ||||||||||
Foreign currency translation gain | 31,000 | 31,000 | ||||||||||
Net loss | (2,688,000) | (113,000) | (2,801,000) | |||||||||
Conversion of related party note payable to common stock (in shares) | 10,552,234 | |||||||||||
Conversion of related party note payable to common stock | $ 11,000 | 2,989,000 | 3,000,000 | |||||||||
Balance (in shares) at Jun. 30, 2022 | 27,779,440 | |||||||||||
Balance at Jun. 30, 2022 | $ 28,000 | 265,596,000 | (259,521,000) | 76,000 | (670,000) | 5,509,000 | ||||||
Stock-based compensation expense | 70,000 | 70,000 | ||||||||||
Issuance of common stock via at-the-market offering, net (in shares) | 3,541,922 | |||||||||||
Issuance of common stock via at-the-market offering, net | $ 3,000 | $ 990,000 | $ 993,000 | |||||||||
Related party convertible note price reset | 1,075,000 | 1,075,000 | ||||||||||
Foreign currency translation gain | 22,000 | 22,000 | ||||||||||
Net loss | (3,240,000) | (163,000) | (3,403,000) | |||||||||
Balance (in shares) at Sep. 30, 2022 | 31,321,362 | |||||||||||
Balance at Sep. 30, 2022 | $ 31,000 | $ 267,731,000 | $ (262,761,000) | $ 98,000 | $ (833,000) | $ 4,266,000 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (8,239,000) | $ (8,994,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 666,000 | 477,000 |
Stock based compensation expense | 184,000 | 2,449,000 |
Amortization of debt discount, net | 1,897,000 | 2,723,000 |
Reserve for excess and slow-moving inventories | 654,000 | 336,000 |
Gain on extinguishment of debt | (652,000) | |
Net change in operating assets and liabilities: | ||
Accounts receivable | (1,323,000) | (1,190,000) |
Inventories | 582,000 | (742,000) |
Prepaid expenses and other assets | 757,000 | (260,000) |
Accounts payable | (210,000) | 145,000 |
Interest payable – related party | (1,132,000) | (413,000) |
Accrued payroll and related expenses | 145,000 | 111,000 |
Deferred revenue – short-term | 122,000 | 334,000 |
Other current liabilities | 446,000 | (271,000) |
Long-term deferred revenue and other noncurrent liabilities | (650,000) | (347,000) |
Net cash used in operating activities | (6,101,000) | (6,294,000) |
Cash flows from investing activities: | ||
Capital expenditures | (308,000) | (64,000) |
Net cash used in investing activities | (308,000) | (64,000) |
Cash flows from financing activities: | ||
Proceeds from issuance of common stock, net of expenses | 3,037,000 | 6,832,000 |
Net cash provided by financing activities | 3,037,000 | 6,832,000 |
Effects of foreign currency rate changes on cash and cash equivalents | (5,000) | (1,000) |
Net increase (decrease) in cash, cash equivalents and restricted cash | (3,377,000) | 473,000 |
Cash, cash equivalents and restricted cash at beginning of period | 7,280,000 | 7,161,000 |
Cash, cash equivalents and restricted cash at end of period | 3,903,000 | 7,634,000 |
Supplemental disclosures of cash flow information: | ||
Cash paid for related party interest | 2,628,000 | 2,082,000 |
Cash paid for interest | 180,000 | 180,000 |
Right-to-use asset acquired under operating lease | 3,863,000 | |
Related party promissory note converted to common stock | 3,000,000 | |
Related party convertible note price reset | $ 3,763,000 | |
Transfer of inventory to fixed assets | $ 181,000 |
Note 1 - Description of Busines
Note 1 - Description of Business | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. Description of Business ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”) develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. Since the 1990’s, ThermoGenesis Holdings has been a pioneer in, and a leading provider of automated systems that isolate, purify and cryogenically store units of hematopoietic stem and progenitor cells for the cord blood banking industry. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA. Medical Device Products for Automated Cell Processing The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and the CAR-TXpress™ platform for large scale cell manufacturing services. All product lines are reporting as a single reporting segment in the financial statements. Planned CDMO Business In March 2022, our Board of Directors approved the planned expansion of the Company’s business to include contract development and manufacturing services for cell and cell-based gene therapies. The Company plans to develop and build-out the capabilities to become a Contract Development and Manufacturing Organization (“CDMO”) for cell and cell-based gene therapies by partnering with Boyalife Genomics Tianjin Ltd., a China-based CDMO (“Boyalife Genomics”), to in-license certain know-how and other intellectual property from Boyalife Genomics, and by leasing and building out a cell manufacturing facility in Sacramento, California. We intend to leverage our existing technology and combine it with the in-licensed technologies to develop a proprietary manufacturing platform for cell manufacturing activities and other cell manufacturing solutions for clients with therapeutic candidates in various stages of development. We are targeting the launch of our CDMO services to customers in 2023. |
Note 2 - Going Concern
Note 2 - Going Concern | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | 2. Going Concern The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future. The Company may need to raise additional capital to grow its business, fund operating expenses and make interest payments. The Company’s ability to fund its liquidity needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the Company, if at all. These factors and other indicators raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing date of this report. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. |
Note 3 - Summary of Significant
Note 3 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | 3. Summary of Significant Accounting Polices There have been no material changes in the Company’s significant accounting policies to those disclosed in the 2021 Annual Report. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the Company’s fiscal year ended December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings’ Annual Report on Form 10-K for the year ended December 31, 2021. Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an 80% ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section. Recently Adopted Accounting Standards On January 1, 2022, we adopted Accounting Standards Update (“ASU”) 2020-06 “ Debt-Debt with Conversion and Other Options ( Subtopic 470-20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815-40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, |
Note 4 - Related Party Transact
Note 4 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 4. Related Party Transactions Convertible Promissory Note and Revolving Credit Agreement In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Group (USA), Inc. (the “Lender”), which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to March 6, 2023 (the “Maturity Date”). The Company performed a debt extinguishment vs. modification analysis. The analysis determined that the extension would be considered an extinguishment from an accounting standpoint, due to the change in the value of the conversion option. In June 2022, the Lender converted a total of $3,000,000 of the outstanding balance of the convertible note into 10,552,234 shares of our common stock. As of September 30, 2022 and December 31, 2021, the outstanding principle balance of the Loan was $7,000,000 and $10,000,000, respectively. The Credit Agreement and the Convertible Promissory Note issued thereunder, as amended (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. The Loan can be prepaid in whole or in part by the Company at any time without penalty. The following summarizes the Note: Maturity Date Stated Interest Rate Conversion Price Face Value Debt Discount Carrying Value September 30, 2022 3/6/2023 22 % $ 0.21 $ 7,000,000 $ (1,867,000 ) $ 5,133,000 December 31, 2021 3/6/2022 22 % $ 1.80 $ 10,000,000 $ (755,000 ) $ 9,245,000 The Note includes a down-round anti-dilution provision that lowers its conversion price if the Company sells shares of common stock or issues convertible debt at a lower price per share. In 2022, the anti-dilution provision was triggered three times, as noted below: In February 2022, when the conversion price of the Note was at $1.80 per share, the Company sold shares of common stock at $0.64 per share. This resulted in a triggering event lowering the conversion price of the Note to that value. The Company determined that it created an incremental value of $213,000 which was treated as a debt discount and amortized over the remaining term of the Note. In June 2022, the Company sold shares of common stock at $0.28 per share, resulting in a down round triggering event lowering the conversion price of the Note to that value. The triggering event created an incremental value of $2,475,000 which was treated as a debt discount and will be amortized over the remaining term of the Note. In July 2022, the Company modified a convertible debt agreement, lowering the conversion price of the debt to $0.21 per share, resulting in a down round triggering event lowering the conversion price of the Note to that value. The triggering event created an incremental value of $1,075,000 which was treated as a debt discount and will be amortized over the remaining term of the Note. A Black-Scholes pricing model was utilized to determine the change in the before and after incremental value of the conversion option at each triggering event, with the following inputs: February 2022 June 2022 July 2022 Conversion price before $ 1.80 $ 0.64 $ 0.28 Conversion price after $ 0.64 $ 0.28 $ 0.21 Term (years) 0.02 0.69 0.61 Volatility 39.53 % 85.6 % 99.5 % Dividend rate 0 % 0 % 0 % Risk free rate 1.97 % 3.2 % 2.8 % The Company amortized $940,000 and $1,897,000 of debt discount to interest expense for the three and nine months ended September 30, 2022. The amortization included $742,000, which related to accelerated amortization for the portion of the Note that was converted in June 2022. In addition to the amortization, the Company also recorded interest expense of $394,000 and $1,496,000 for the three and nine months ended September 30, 2022, and $562,000 and $1,668,000 for the three and nine months ended September 30, 2021. The interest payable balance as of September 30, 2022 and December 31, 2021 was $1,099,000 and $2,231,000, respectively. Boyalife Genomics On March 24, 2022, the Company entered into a License and Technology Access Agreement with Boyalife Genomics Tianjin Ltd. (“Boyalife Genomics”), a China-based CDMO and an affiliate of ThermoGenesis’ Chairman and Chief Executive Officer, Chris Xu, Ph.D. The agreement provides for a U.S. license to certain existing and future know-how and other intellectual property relating to cell manufacturing and related processes. The Company plans to develop and operate the CDMO cell therapy manufacturing business through a newly formed division named TG Biosynthesis. Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one or more of Boyalife Genomics’ granted U.S. patents and a royalty of 5.0% of other products and services covered by other licensed intellectual property. In the three and nine months ended September 30, 2022, no sales were recorded under the license agreement and no royalty payments were made to Boyalife Genomics. |
Note 5 - Related Party Lease
Note 5 - Related Party Lease | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 5. Related Party Lease Z3 Investment On March 24, 2022, the Company entered into a five 5-year The Company performed an analysis of the lease and determined it to be an operating lease. A right-of-use asset and lease obligation were recorded at inception of the lease. Operating Lease Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we use the Company’s cost of capital based on existing debt instruments. We recognize the expense for this lease on a straight-line basis over the lease term. The following summarizes the Company’s operating lease: September 30, 2022 Right-of-use operating lease assets – related party, net $ 3,653,000 Current lease liability (included in other current liabilities) 397,000 Non-current lease liability – related party 3,622,000 Weighted average remaining lease term 5.00 Discount rate 22 % Maturities of lease liabilities by year for our operating lease are as follows: 2022 (Remaining) $ 311,000 2023 1,256,000 2024 1,307,000 2025 1,359,000 2026 1,428,000 Thereafter 1,133,000 Total lease payments $ 6,794,000 Less: imputed interest (2,775,000 ) Present value of operating lease liabilities $ 4,019,000 Statement of Cash Flows Cash paid for amounts included in the measurement of operating lease liabilities was $138,000 and $277,000 for the three and nine months ended September 30, 2022, respectively. |
Note 6 - Convertible Promissory
Note 6 - Convertible Promissory Note | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 6. Convertible Promissory Note July 2019 Note On July 23, 2019, the Company entered into a private placement with the Accredited Investor, pursuant to which the Company issued and sold to such investor an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). The July 2019 Note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s common stock on the date of conversion (subject to a floor conversion price of $0.50). The July 2019 Note bears interest at a rate of twenty-four percent (24%) On July 25, 2022, the Company entered into an amendment to the July 2019 Note, which extended the maturity date of the July 2019 Note to January 31, 2023 and modified when interest is due from quarterly to January 31, 2023. The amendment also (i) deleted the market price-based conversion right, which previously allowed for the July 2019 Note to be converted at a conversion price of 90% of the Company’s stock price on the day of conversion (subject to a $0.50 floor); and (ii) changed to a fixed conversion price to $0.21 per share, provided that in the event that the Company issues shares, options, warrants, or convertible securities, at an effective price per common share lower than $0.21, then the conversion price will be adjusted to such lower issuance price. The Company performed a debt extinguishment vs. modification analysis on the amendment to the July 2019 Note and determined that the extension would be considered an extinguishment, due to an increase of more than 10% to the value of the embedded conversion option. No gain or loss was recorded in the consolidated statement of operations for the quarter ended September 30, 2022 as it was determined that the fair value of the amendment of the July 2019 Note and accrued interest was $1,020,000 both before and after the extension. The following summarizes the July 2019 Note: Maturity Date Stated Interest Rate Conversion Price Carrying Value September 30, 2022 1/31/2023 24 % $ 0.21 $ 1,000,000 December 31, 2021 7/31/2022 24 % $ 0.91 $ 813,000 The Company recorded amortization of debt discount on the July 2019 Note of $80,000 and $241,000 for the three and nine months ended September 30, 2021. Interest expense related to the July 2019 Note was $60,000 and $180,000 for the three and nine months ended September 30, 2022 and 2021. |
Note 7 - Stockholders' Equity
Note 7 - Stockholders' Equity | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 7. Stockholders Equity Common Stock On February 3, 2022, the Company entered into Amendment No. 2 to the At the Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC to further increase the maximum aggregate offering price of shares of Common Stock that may be offered and sold from time to time under the Offering Agreement from $15,280,000 to $ 19,555,000 Equity Plans On January 13, 2022, the Company’s stockholders approved an amendment of the Company’s Amended 2016 Equity Incentive Plan to increase the aggregate number of shares of the Company’s common stock that may be issued under the plan from 392,500 shares to 1,200,000 shares. Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at September 30: 2022 2021 Common stock equivalents of convertible promissory notes and accrued interest 43,612,759 7,071,241 Warrants – other 653,248 653,248 Stock options 287,081 366,595 Total 44,553,088 8,091,084 |
Note 8 - Revenue
Note 8 - Revenue | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 8. Revenue The following table presents net sales by geographic areas: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 1,535,000 $ 1,517,000 $ 4,973,000 $ 3,558,000 China 364,000 1,357,000 1,570,000 1,445,000 Thailand 2,000 -- 10,000 400,000 Other 214,000 284,000 1,254,000 1,473,000 Total $ 2,115,000 $ 3,158,000 $ 7,807,000 $ 6,876,000 The following tables summarize the revenues by product line and type: Three Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,034,000 $ 75,000 $ -- $ 1,109,000 BioArchive 201,000 321,000 -- 522,000 CAR-TXpress 190,000 44,000 72,000 306,000 Manual Disposables 150,000 -- -- 150,000 Other 20,000 -- 8,000 28,000 Total $ 1,595,000 $ 440,000 $ 80,000 $ 2,115,000 Nine Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,668,000 $ 171,000 $ -- $ 4,839,000 BioArchive 694,000 924,000 -- 1,618,000 CAR-TXpress 551,000 146,000 214,000 911,000 Manual Disposables 357,000 -- -- 357,000 Other 59,000 -- 23,000 82,000 Total $ 6,329,000 $ 1,241,000 $ 237,000 $ 7,807,000 Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 21,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues recognized during the three and nine months ended September 30, 2022 that were included in the beginning balance of deferred revenue were $144,000 and $620,000, respectively. Short-term deferred revenues were $841,000 and $719,000 at September 30, 2022 and December 31, 2021, respectively. Long-term deferred revenue was $1,014,000 and $1,244,000 at September 30, 2022 and December 31, 2021, respectively. Backlog of Remaining Customer Performance Obligations The following table represents revenue expected to be recognized in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period: Remainder of 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 407,000 0.25 $ 1,089,000 1 $ 664,000 1 $ 176,000 1 $ -- 1 $ 2,336,000 Device revenue (1) 21,000 0.25 733,000 1 41,000 1 -- 1 -- 1 795,000 Exclusivity fee 71,000 0.25 286,000 1 286,000 1 286,000 1 190,000 1 1,119,000 Other 3,000 0.25 13,000 1 13,000 1 13,000 1 122,000 1 164,000 Total $ 502,000 0.25 $ 2,121,000 1 $ 1,004,000 1 $ 475,000 1 $ 312,000 1 $ 4,414,000 (1) Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China. |
Note 9 - Concentrations
Note 9 - Concentrations | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | 9. Concentrations The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable as follows: Accounts Receivable September 30, 2022 December 31, 2021 Customer 1 49 % -- % Customer 2 15 % 28 % Customer 3 13 % -- % Customer 4 1 % 27 % Revenues Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Customer 1 36 % 22 % 36 % 15 % Customer 2 14 % 1 % 6 % 1 % Customer 3 1 % 44 % 14 % 20 % |
Note 10 - Subsequent Events
Note 10 - Subsequent Events | 9 Months Ended |
Sep. 30, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 10. Subsequent Events On October 25, 2022, the Company announced the pricing of a public offering (the "Offering") of an aggregate of 11,783,572 units (the "Units") and 2,892,858 pre-funded units (the "Pre-Funded Units”) for a purchase price of $0.14 per unit, resulting in aggregate gross proceeds of approximately $2,055,000. The Offering closed on October 28, 2022. Each Unit sold in the Offering consisted of one one one one one one one fifth |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Adopted Accounting Standards Debt-Debt with Conversion and Other Options ( Subtopic 470-20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815-40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, |
Note 4 - Related Party Transa_2
Note 4 - Related Party Transactions (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Related Party Transactions [Table Text Block] | Maturity Date Stated Interest Rate Conversion Price Face Value Debt Discount Carrying Value September 30, 2022 3/6/2023 22 % $ 0.21 $ 7,000,000 $ (1,867,000 ) $ 5,133,000 December 31, 2021 3/6/2022 22 % $ 1.80 $ 10,000,000 $ (755,000 ) $ 9,245,000 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | February 2022 June 2022 July 2022 Conversion price before $ 1.80 $ 0.64 $ 0.28 Conversion price after $ 0.64 $ 0.28 $ 0.21 Term (years) 0.02 0.69 0.61 Volatility 39.53 % 85.6 % 99.5 % Dividend rate 0 % 0 % 0 % Risk free rate 1.97 % 3.2 % 2.8 % |
Note 5 - Related Party Lease (T
Note 5 - Related Party Lease (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Lease, Cost [Table Text Block] | September 30, 2022 Right-of-use operating lease assets – related party, net $ 3,653,000 Current lease liability (included in other current liabilities) 397,000 Non-current lease liability – related party 3,622,000 Weighted average remaining lease term 5.00 Discount rate 22 % |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | 2022 (Remaining) $ 311,000 2023 1,256,000 2024 1,307,000 2025 1,359,000 2026 1,428,000 Thereafter 1,133,000 Total lease payments $ 6,794,000 Less: imputed interest (2,775,000 ) Present value of operating lease liabilities $ 4,019,000 |
Note 6 - Convertible Promisso_2
Note 6 - Convertible Promissory Note (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Convertible Debt [Table Text Block] | Maturity Date Stated Interest Rate Conversion Price Carrying Value September 30, 2022 1/31/2023 24 % $ 0.21 $ 1,000,000 December 31, 2021 7/31/2022 24 % $ 0.91 $ 813,000 |
Note 7 - Stockholders' Equity (
Note 7 - Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | 2022 2021 Common stock equivalents of convertible promissory notes and accrued interest 43,612,759 7,071,241 Warrants – other 653,248 653,248 Stock options 287,081 366,595 Total 44,553,088 8,091,084 |
Note 8 - Revenue (Tables)
Note 8 - Revenue (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 United States $ 1,535,000 $ 1,517,000 $ 4,973,000 $ 3,558,000 China 364,000 1,357,000 1,570,000 1,445,000 Thailand 2,000 -- 10,000 400,000 Other 214,000 284,000 1,254,000 1,473,000 Total $ 2,115,000 $ 3,158,000 $ 7,807,000 $ 6,876,000 Three Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,034,000 $ 75,000 $ -- $ 1,109,000 BioArchive 201,000 321,000 -- 522,000 CAR-TXpress 190,000 44,000 72,000 306,000 Manual Disposables 150,000 -- -- 150,000 Other 20,000 -- 8,000 28,000 Total $ 1,595,000 $ 440,000 $ 80,000 $ 2,115,000 Nine Months Ended September 30, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,668,000 $ 171,000 $ -- $ 4,839,000 BioArchive 694,000 924,000 -- 1,618,000 CAR-TXpress 551,000 146,000 214,000 911,000 Manual Disposables 357,000 -- -- 357,000 Other 59,000 -- 23,000 82,000 Total $ 6,329,000 $ 1,241,000 $ 237,000 $ 7,807,000 Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 21,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] | Remainder of 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 407,000 0.25 $ 1,089,000 1 $ 664,000 1 $ 176,000 1 $ -- 1 $ 2,336,000 Device revenue (1) 21,000 0.25 733,000 1 41,000 1 -- 1 -- 1 795,000 Exclusivity fee 71,000 0.25 286,000 1 286,000 1 286,000 1 190,000 1 1,119,000 Other 3,000 0.25 13,000 1 13,000 1 13,000 1 122,000 1 164,000 Total $ 502,000 0.25 $ 2,121,000 1 $ 1,004,000 1 $ 475,000 1 $ 312,000 1 $ 4,414,000 |
Note 9 - Concentrations (Tables
Note 9 - Concentrations (Tables) | 9 Months Ended |
Sep. 30, 2022 | |
Notes Tables | |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | September 30, 2022 December 31, 2021 Customer 1 49 % -- % Customer 2 15 % 28 % Customer 3 13 % -- % Customer 4 1 % 27 % Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Customer 1 36 % 22 % 36 % 15 % Customer 2 14 % 1 % 6 % 1 % Customer 3 1 % 44 % 14 % 20 % |
Note 3 - Summary of Significa_2
Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Jan. 01, 2022 | Dec. 31, 2021 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance | $ 4,266,000 | $ 5,509,000 | $ 1,282,000 | $ 3,397,000 | $ 6,168,000 | $ 7,869,000 | $ 10,430,000 | $ 5,870,000 | |
Retained Earnings [Member] | |||||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance | (262,761,000) | (259,521,000) | (256,833,000) | (264,662,000) | (262,009,000) | (260,235,000) | (255,696,000) | (253,283,000) | |
Additional Paid-in Capital [Member] | |||||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance | $ 267,731,000 | $ 265,596,000 | $ 258,614,000 | 268,447,000 | $ 268,336,000 | $ 268,244,000 | $ 266,145,000 | $ 259,058,000 | |
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member] | |||||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance | (942,000) | ||||||||
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member] | Convertible Debt [Member] | |||||||||
Debt Instrument, Unamortized Discount, Total | $ (942,000) | ||||||||
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member] | Retained Earnings [Member] | |||||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance | 9,739,000 | 9,739,000 | |||||||
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2020-06 [Member] | Additional Paid-in Capital [Member] | |||||||||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance | $ (10,681,000) | $ (10,681,000) | |||||||
CAR-TXpress [Member] | |||||||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 20% | ||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 80% |
Note 4 - Related Party Transa_3
Note 4 - Related Party Transactions (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||||
Jun. 30, 2022 | Mar. 24, 2022 | Jun. 30, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Jul. 31, 2022 | Feb. 28, 2022 | Dec. 31, 2021 | Mar. 31, 2017 | |
Amortization of Debt Discount (Premium) | $ 1,897,000 | $ 2,723,000 | |||||||||
Interest Paid, Excluding Capitalized Interest, Operating Activities | 180,000 | 180,000 | |||||||||
ImmuneCyte [Member] | |||||||||||
Percent of Ownership Interest Transferred | 8.64% | ||||||||||
Royalty, Percent of Annual Net Sales, US Patents | 7.50% | ||||||||||
Royalty, Percent of Annual Net Sales, Other Licensed Intellectual Property | 5% | ||||||||||
Convertible Note Converted into Common Stock [Member] | |||||||||||
Debt Conversion, Original Debt, Amount | $ 3,000,000 | ||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 10,552,234 | ||||||||||
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member] | |||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 10,000,000 | ||||||||||
Long-Term Line of Credit, Total | $ 7,000,000 | $ 7,000,000 | $ 10,000,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 22% | 22% | |||||||||
Debt Instrument, Convertible, Conversion Price | $ 0.28 | $ 0.28 | $ 0.21 | $ 0.64 | $ 1.80 | ||||||
Debt Instrument, Unamortized Discount, Total | $ 2,475,000 | $ 2,475,000 | $ 1,075,000 | $ 213,000 | |||||||
Amortization of Debt Discount (Premium) | $ 742,000 | $ 940,000 | $ 1,897,000 | ||||||||
Interest Paid, Excluding Capitalized Interest, Operating Activities | 394,000 | $ 562,000 | 1,496,000 | $ 1,668,000 | |||||||
Interest Payable | $ 1,099,000 | $ 1,099,000 | $ 2,231,000 |
Note 4 - Related Party Transa_4
Note 4 - Related Party Transactions - Summarizes the Note (Details) - Boyalife Asset Holding II [Member] - Convertible Debt [Member] - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2022 | Dec. 31, 2021 | |
Maturity Date | Mar. 06, 2023 | Mar. 06, 2022 |
Stated Interest Rate | 22% | 22% |
Conversion Price (in dollars per share) | $ 0.21 | $ 1.80 |
Face Value | $ 7,000,000 | $ 10,000,000 |
Debt Discount | (1,867,000) | (755,000) |
Carrying Value | $ 5,133,000 | $ 9,245,000 |
Note 4 - Related Party Transa_5
Note 4 - Related Party Transactions - Black-Scholes Pricing Model (Details) | Jul. 30, 2022 | Jun. 30, 2022 | Feb. 28, 2022 |
Measurement Input, Conversion Price Before [Member] | |||
Measurement input | 0.28 | 0.64 | 1.80 |
Measurement Input, Conversion Price [Member] | |||
Measurement input | 0.21 | 0.28 | 0.64 |
Measurement Input, Expected Term [Member] | |||
Measurement input | 0.61 | 0.69 | 0.02 |
Measurement Input, Price Volatility [Member] | |||
Measurement input | 0.995 | 0.856 | 0.3953 |
Measurement Input, Expected Dividend Rate [Member] | |||
Measurement input | 0 | 0 | 0 |
Measurement Input, Risk Free Interest Rate [Member] | |||
Measurement input | 0.028 | 0.032 | 0.0197 |
Note 5 - Related Party Lease (D
Note 5 - Related Party Lease (Details Textual) - Lease Agreement with Z3 Investment LLC [Member] | 3 Months Ended | 9 Months Ended | |
Mar. 24, 2022 USD ($) a | Sep. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | |
Lessee, Operating Lease, Term of Contract | 5 years | ||
Area of Real Estate Property | a | 35,000 | ||
First Six Months, Rental Expense, Operating Leases | $ 46,000 | ||
Second Six Months, Rental Expense, Operating Lease | $ 104,000 | ||
Percent Increase, Annual Rental Expense | 4% | ||
Operating lease, Operating Expenses, Per Month | $ 5,000 | ||
Lessee, Operating Lease, Renewal Term (Year) | 5 years | ||
Operating Lease, Payments | $ 138,000 | $ 277,000 |
Note 5 - Related Party Lease -
Note 5 - Related Party Lease - Lease Information (Details) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
Right-of-use operating lease assets – related party, net | $ 426,000 | $ 571,000 |
Non-current lease liability – related party | 205,000 | $ 398,000 |
Lease Agreement with Z3 Investment LLC [Member] | ||
Right-of-use operating lease assets – related party, net | 3,653,000 | |
Current lease liability (included in other current liabilities) | 397,000 | |
Non-current lease liability – related party | $ 3,622,000 | |
Weighted average remaining lease term (Year) | 5 years | |
Discount rate | 22% |
Note 5 - Related Party Lease _2
Note 5 - Related Party Lease - Maturities of Lease Liabilities (Details) - Lease Agreement with Z3 Investment LLC [Member] | Sep. 30, 2022 USD ($) |
2022 (Remaining) | $ 311,000 |
2023 | 1,256,000 |
2024 | 1,307,000 |
2025 | 1,359,000 |
2026 | 1,428,000 |
Thereafter | 1,133,000 |
Total lease payments | 6,794,000 |
Less: imputed interest | (2,775,000) |
Present value of operating lease liabilities | $ 4,019,000 |
Note 6 - Convertible Promisso_3
Note 6 - Convertible Promissory Note (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |||||
Jul. 23, 2019 | Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Jul. 25, 2022 | Dec. 31, 2021 | |
Amortization of Debt Discount (Premium) | $ 1,897,000 | $ 2,723,000 | |||||
Interest Expense, Debt, Total | $ 60,000 | ||||||
Convertible Debt [Member] | The July 2019 Note [Member] | |||||||
Debt Instrument, Face Amount | $ 1,000,000 | ||||||
Debt Instrument, Convertible, Conversion Price | $ 1.80 | $ 0.21 | $ 0.21 | $ 0.21 | $ 0.91 | ||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 90% | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 24% | 24% | 24% | 24% | |||
Long-Term Debt, Fair Value | $ 1,020,000 | $ 1,020,000 | |||||
Amortization of Debt Discount (Premium) | $ 80,000 | 241,000 | |||||
Interest Expense, Debt, Total | $ 60,000 | $ 180,000 | $ 180,000 | ||||
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member] | |||||||
Debt Instrument, Convertible, Conversion Price | $ 0.50 |
Note 6 - Convertible Promisso_4
Note 6 - Convertible Promissory Note - Convertible Promissory Note (Details) - Convertible Debt [Member] - The July 2019 Note [Member] - USD ($) | 9 Months Ended | ||||
Sep. 30, 2022 | Sep. 30, 2021 | Jul. 25, 2022 | Dec. 31, 2021 | Jul. 23, 2019 | |
Maturity Date | Jul. 31, 2022 | Jul. 31, 2022 | |||
Stated Interest Rate | 24% | 24% | 24% | ||
Conversion Price (in dollars per share) | $ 0.21 | $ 0.21 | $ 0.91 | $ 1.80 | |
Carrying Value | $ 1,000,000 | $ 813,000 |
Note 7 - Stockholders' Equity_2
Note 7 - Stockholders' Equity (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Jan. 13, 2022 | Jun. 30, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | Mar. 31, 2022 | Feb. 03, 2022 | |
Proceeds from Issuance of Common Stock, Net | $ 3,037,000 | $ 6,832,000 | ||||
The 2016 Plan [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized | 392,500 | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized | 1,200,000 | |||||
At The Market Offering Agreement [Member] | ||||||
Maximum Offering Price for Issuance of Common Stock | $ 18,573,000 | |||||
Additional Common Stock, Shares Authorized | $ 4,275,000 | |||||
Stock Issued During Period, Shares, New Issues | 1,450,000 | 8,857,344 | ||||
Proceeds from Issuance of Common Stock | $ 3,293,000 | |||||
Shares Issued, Average Price Per Share | $ 0.37 | |||||
Proceeds from Issuance of Common Stock, Net | $ 3,037,000 | |||||
Payments of Stock Issuance Costs | $ 256,000 | |||||
Minimum [Member] | At The Market Offering Agreement [Member] | ||||||
Maximum Offering Price for Issuance of Common Stock | 15,280,000 | |||||
Maximum [Member] | At The Market Offering Agreement [Member] | ||||||
Maximum Offering Price for Issuance of Common Stock | $ 19,555,261 |
Note 7 - Stockholders' Equity -
Note 7 - Stockholders' Equity - Anti-dilutive Securities (Details) - shares | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2021 | |
Anti-dilutive securities (in shares) | 44,553,088 | 8,091,084 |
Convertible Debt Securities [Member] | ||
Anti-dilutive securities (in shares) | 43,612,759 | 7,071,241 |
Warrant, Other [Member] | ||
Anti-dilutive securities (in shares) | 653,248 | 653,248 |
Share-Based Payment Arrangement, Option [Member] | ||
Anti-dilutive securities (in shares) | 287,081 | 366,595 |
Note 8 - Revenue (Details Textu
Note 8 - Revenue (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |
Sep. 30, 2022 | Sep. 30, 2022 | Dec. 31, 2021 | |
Contract with Customer, Liability, Revenue Recognized | $ 144,000 | $ 620,000 | |
Contract with Customer, Liability, Current | 841,000 | 841,000 | $ 719,000 |
Contract with Customer, Liability, Noncurrent | $ 1,014,000 | $ 1,014,000 | $ 1,244,000 |
Note 8 - Revenue - Revenues (De
Note 8 - Revenue - Revenues (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Net revenues | $ 2,115,000 | $ 3,158,000 | $ 7,807,000 | $ 6,876,000 |
Device Revenue [Member] | ||||
Net revenues | 1,595,000 | 2,662,000 | 6,329,000 | 5,190,000 |
Service [Member] | ||||
Net revenues | 440,000 | 400,000 | 1,241,000 | 1,413,000 |
Other [Member] | ||||
Net revenues | 80,000 | 96,000 | 237,000 | 273,000 |
Device [Member] | AXP [Member] | ||||
Net revenues | 1,109,000 | 2,310,000 | 4,839,000 | 3,670,000 |
Device [Member] | AXP [Member] | Device Revenue [Member] | ||||
Net revenues | 1,034,000 | 2,217,000 | 4,668,000 | 3,490,000 |
Device [Member] | AXP [Member] | Service [Member] | ||||
Net revenues | 75,000 | 72,000 | 171,000 | 159,000 |
Device [Member] | AXP [Member] | Other [Member] | ||||
Net revenues | 21,000 | 21,000 | ||
Device [Member] | BioArchive [Member] | ||||
Net revenues | 522,000 | 518,000 | 1,618,000 | 1,817,000 |
Device [Member] | BioArchive [Member] | Device Revenue [Member] | ||||
Net revenues | 201,000 | 221,000 | 694,000 | 652,000 |
Device [Member] | BioArchive [Member] | Service [Member] | ||||
Net revenues | 321,000 | 297,000 | 924,000 | 1,165,000 |
Device [Member] | CAR-TXpress [Member] | ||||
Net revenues | 306,000 | 262,000 | 911,000 | 1,005,000 |
Device [Member] | CAR-TXpress [Member] | Device Revenue [Member] | ||||
Net revenues | 190,000 | 160,000 | 551,000 | 702,000 |
Device [Member] | CAR-TXpress [Member] | Service [Member] | ||||
Net revenues | 44,000 | 31,000 | 146,000 | 89,000 |
Device [Member] | CAR-TXpress [Member] | Other [Member] | ||||
Net revenues | 72,000 | 71,000 | 214,000 | 214,000 |
Device [Member] | Manual Disposables [Member] | ||||
Net revenues | 150,000 | 55,000 | 357,000 | 300,000 |
Device [Member] | Manual Disposables [Member] | Device Revenue [Member] | ||||
Net revenues | 150,000 | 55,000 | 357,000 | 300,000 |
Device [Member] | Other Subsegments [Member] | ||||
Net revenues | 28,000 | 13,000 | 82,000 | 84,000 |
Device [Member] | Other Subsegments [Member] | Device Revenue [Member] | ||||
Net revenues | 20,000 | 9,000 | 59,000 | 46,000 |
Device [Member] | Other Subsegments [Member] | Other [Member] | ||||
Net revenues | 8,000 | 4,000 | 23,000 | 38,000 |
UNITED STATES | ||||
Net revenues | 1,535,000 | 1,517,000 | 4,973,000 | 3,558,000 |
CHINA | ||||
Net revenues | 364,000 | 1,357,000 | 1,570,000 | 1,445,000 |
THAILAND | ||||
Net revenues | 2,000 | 10,000 | 400,000 | |
All Other Countries [Member] | ||||
Net revenues | $ 214,000 | $ 284,000 | $ 1,254,000 | $ 1,473,000 |
Note 8 - Revenue - Remaining Pe
Note 8 - Revenue - Remaining Performance Obligations (Details) | Sep. 30, 2022 USD ($) | |
Revenue, Remaining Performance Obligation, Amount | $ 4,414,000 | |
Service [Member] | ||
Revenue, Remaining Performance Obligation, Amount | 2,336,000 | |
Device Revenue [Member] | ||
Revenue, Remaining Performance Obligation, Amount | 795,000 | [1] |
Exclusivity Fee [Member] | ||
Revenue, Remaining Performance Obligation, Amount | 1,119,000 | |
Product and Service, Other [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 164,000 | |
[1]Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China. |
Note 8 - Revenue - Remaining _2
Note 8 - Revenue - Remaining Performance Obligations 2 (Details) | Sep. 30, 2022 USD ($) | |
Revenue, Remaining Performance Obligation, Amount | $ 4,414,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 502,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 2,121,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 1,004,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 475,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 312,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Service [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 2,336,000 | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 407,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 1,089,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 664,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 176,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Device Revenue [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 795,000 | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 21,000 | [1] |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 733,000 | [1] |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | [1] |
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 41,000 | [1] |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | [1] |
Exclusivity Fee [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 1,119,000 | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 71,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 286,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 286,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 286,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 190,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Product and Service, Other [Member] | ||
Revenue, Remaining Performance Obligation, Amount | $ 164,000 | |
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 3,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 3 months | |
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 13,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 13,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 13,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | ||
Revenue, Remaining Performance Obligation, Amount | $ 122,000 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year) | 1 year | |
[1]Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China. |
Note 9 - Concentrations - Accou
Note 9 - Concentrations - Accounts Receivables and Revenues (Details) - Customer Concentration Risk [Member] | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Accounts Receivable [Member] | Customer 1 [Member] | |||||
Concentration Risk, Percentage | 49% | ||||
Accounts Receivable [Member] | Customer 2 [Member] | |||||
Concentration Risk, Percentage | 15% | 28% | |||
Accounts Receivable [Member] | Customer 3 [Member] | |||||
Concentration Risk, Percentage | 13% | ||||
Accounts Receivable [Member] | Customer 4 [Member] | |||||
Concentration Risk, Percentage | 27% | ||||
Revenue from Contract with Customer Benchmark [Member] | Customer 1 [Member] | |||||
Concentration Risk, Percentage | 36% | 0.48% | 36% | 0.10% | |
Revenue from Contract with Customer Benchmark [Member] | Customer 2 [Member] | |||||
Concentration Risk, Percentage | 14% | 1% | 6% | 1% | |
Revenue from Contract with Customer Benchmark [Member] | Customer 3 [Member] | |||||
Concentration Risk, Percentage | 1% | 44% | 14% | 20% |
Note 10 - Subsequent Events (De
Note 10 - Subsequent Events (Details Textual) - Subsequent Event [Member] | Oct. 25, 2022 USD ($) $ / shares shares |
Shares Issued, Price Per Share | $ / shares | $ 0.14 |
Proceeds from Issuance or Sale of Equity, Total | $ | $ 2,055,000 |
The Units Warrants [Member] | |
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 |
Pre-funded Units Warrant [Member] | |
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 |
Units Common Warrant [Member] | |
Units Issued, Warrants Per Unit | 1 |
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 |
Offering Warrants [Member] | |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.14 |
Warrants and Rights Outstanding, Term | 5 years |
Warrants and Rights Outstanding, Warrants Exercised | 2,892,858 |
Units [Member] | |
Stock Issued During Period, Units, New Issues | 11,783,572 |
Units Issued, Common Shares Per Unit | 1 |
Units Issued, Warrants Per Unit | 1 |
Pre-funded Units [Member] | |
Stock Issued During Period, Units, New Issues | 2,892,858 |
Units Issued, Warrants Per Unit | 1 |